J&J, JDRF Partner in Diabetes ResearchBy
Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced that it will invest in a new scientific approach, called disease interception, to find ways to intercept Type 1 diabetes (T1D) using new diagnostic and pre-disease intervention strategies. If successful, this approach has the potential to transform the standard of care in Type 1 diabetes (T1D), said the company.
This new approach to T1D is the first in a series of disease areas to be addressed as part of Janssen's newly announced Disease Interception Accelerator (DIA), an autonomous incubator-like group that seeks to identify the root causes of disease and enable the development of interventions that stop the progression to disease. Janssen scientists will work to develop new diagnostic, therapeutic, or combination approaches for T1D interception by understanding the role of potential triggers and initiating steps on the pathway to T1D.
Janssen researchers will bring to bear the latest basic research insights together with the JDRF, a research and advocacy organization funding T1D research, to inform and accelerate targeted and science-based solutions for T1D. In addition, with the JDRF's insights, Janssen will seek to enhance the underlying clinical research network for overall T1D, which is needed to accelerate basic research and mechanistic-based solutions. Janssen's disease interception approach will integrate innovative science, novel therapeutics, precision diagnostics, and new business models to nurture solutions that intercept disease. As the DIA's first area of focus, T1D research will use the emerging science of immune diagnostics and precision intervention to provide the foundation to intercept other diseases that have immunological underpinnings.
Source: Johnson & Johnson